Collaborations

About 4 results

Drs. Meyers and Wildman were interested in the potential of PDE inhibitors to target a specific protein of interest in Mycobacterium tuberculosis (MTb). BVGH connected them with Dr. Pollastri, who had synthesized a set of PDE inhibitors as potential new drugs for HAT. Dr. Pollastri shared the structures of his compounds with Drs. Meyers and Wildman, who performed virtual docking studies to predict whether the inhibitors might have activity against MTb.

Rates of drug-resistant TB are increasing, and treatments focused on new drug targets are desperately needed. One such potential target is MetAPs, which helps process proteins in Mycobacterium tuberculosis, the bacterium that causes TB. However, GSK’s initial efforts to develop inhibitors of the M. tuberculosis MetAP-1 enzyme were met with disappointing results. GSK shared its data with Dr. Ruminski and colleagues. As a result of this collaboration, CWHM revised its research priorities and placed the TB MetAP-1 inhibitor program on hold, saving an estimated three months of employee time and approximately $50,000 of research costs.

Sanofi provided CWHM researchers with two compounds to evaluate in a rat diarrhea model.

Pfizer provided CWHM researchers with two compounds to evaluate in a rat diarrhea model.